Zymeworks, Inc.
(NYSE : ZYME)

( )
ZYME PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.58%143.130.7%$858.08m
PFEPfizer Inc. -1.24%37.450.9%$834.37m
MRKMerck & Co., Inc. -1.09%77.980.7%$641.32m
BMYBristol-Myers Squibb Co. -1.58%58.731.0%$576.80m
ABBVAbbVie, Inc. -1.45%82.701.9%$573.06m
LLYEli Lilly & Co. -6.92%131.891.1%$497.00m
AZNAstraZeneca Plc -1.11%52.481.2%$212.96m
GSKGlaxoSmithKline Plc 0.43%35.370.2%$153.30m
NVSNovartis AG -3.84%80.950.2%$144.70m
NVONovo Nordisk A/S -2.41%67.970.1%$68.84m
RGENRepligen Corp. -0.96%175.847.1%$66.03m
RPRXRoyalty Pharma Plc -2.32%37.870.2%$62.66m
TPTXTurning Point Therapeutics, Inc. 6.88%100.080.0%$54.47m
SNYSanofi -3.52%47.400.2%$47.65m
AMAGAMAG Pharmaceuticals, Inc. 0.15%13.7022.1%$46.92m

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.